Sun Pharma Aims to Swiftly Reduce Debt Burden Following Organon Acquisition

Sun Pharma's Chairperson Expressed Confidence in Repaying $10 Billion Debt

Sun Pharma's chairperson Dilip Shanghvi has expressed confidence in repaying nearly $10 billion debt as early as possible, allaying investor concerns over its pivot from a cash-rich conservative to a leveraged global drugmaker. This statement was made on April 27, as the company prepares to take on the unprecedented scale of the $11.75 billion transaction.

The deal, the largest-ever by an Indian pharmaceutical firm, is being funded by roughly $2-2.5 billion of cash on hand and the remaining $9.25-9.75 billion would be funded through bridge loans. Shanghvi pointed out that the company's history of aggressive debt repayment will repeat itself, despite the scale of the transaction. The deal is expected to become EPS-accretive from the first year, with the acquired business contributing to Sun Pharma's growth.

The Leverage Math

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

The acquisition pushes Sun's net-debt-to-EBITDA ratio to approximately 2.3x, a stark departure from the company's previous cash-rich status. However, the management insists that the combined entity's cash-generating engine is more than capable of servicing the load. The primary lever for repayment is a projected annual free cash flow of $2.5 billion.

Repayment Strategy

Sun Pharma executives have confirmed that while they intend to maintain current dividend levels to satisfy shareholders, the "bulk of residual cash" will be used to pare principal debt. The repayment strategy isn't just about diversion of existing cash, but also an overhaul of Organon's cost structure. Sun Pharma has identified over $350 million in cost synergies to be realised over the next 2-3 years, largely by applying what Chief Financial Officer (CFO) Jayashree Satagopan calls Sun Pharma's "DNA of running lean and efficient operations."

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Growth Levers

Beyond cost-cutting, Sun Pharma is betting on two growth levers to accelerate the payoff. The company plans to apply its "branded generics playbook" to Organon's $3.5 billion portfolio of established brands, which have seen sluggish growth in recent years. Sun Pharma is planning to use Organon's deep commercial infrastructure in Europe, China, and South Korea, among other countries, to launch its own high-margin specialty products.

The deal effectively transforms Sun Pharma into a top 25 global pharma player, increasing its revenue from innovative medicines to 27 percent, up from 20 percent. It also places Sun Pharma in the top-three global ranking in women's health and a top-seven ranking in biosimilars. By 2030, Sun expects to have 18 countries generating over $100 million in annual revenue, significantly reducing its historical reliance on the volatile US generics market.